346 related articles for article (PubMed ID: 17958029)
1. [The incretin effect: a new therapeutic target in type 2 diabetes].
Féry F
Rev Med Brux; 2007 Sep; 28(4):329-35. PubMed ID: 17958029
[TBL] [Abstract][Full Text] [Related]
2. Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes.
Gautier JF; Fetita S; Sobngwi E; Salaün-Martin C
Diabetes Metab; 2005 Jun; 31(3 Pt 1):233-42. PubMed ID: 16142014
[TBL] [Abstract][Full Text] [Related]
3. Enhancing incretin action for the treatment of type 2 diabetes.
Drucker DJ
Diabetes Care; 2003 Oct; 26(10):2929-40. PubMed ID: 14514604
[TBL] [Abstract][Full Text] [Related]
4. Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus.
Siddiqui NI
Mymensingh Med J; 2009 Jan; 18(1):113-24. PubMed ID: 19182763
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.
Pratley RE; Salsali A
Curr Med Res Opin; 2007 Apr; 23(4):919-31. PubMed ID: 17407649
[TBL] [Abstract][Full Text] [Related]
6. Pancreatic islet dysfunction in type 2 diabetes: a rational target for incretin-based therapies.
Meece J
Curr Med Res Opin; 2007 Apr; 23(4):933-44. PubMed ID: 17407650
[TBL] [Abstract][Full Text] [Related]
7. Incretins: their physiology and application in the treatment of diabetes mellitus.
Tasyurek HM; Altunbas HA; Balci MK; Sanlioglu S
Diabetes Metab Res Rev; 2014 Jul; 30(5):354-71. PubMed ID: 24989141
[TBL] [Abstract][Full Text] [Related]
8. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.
Herman GA; Bergman A; Stevens C; Kotey P; Yi B; Zhao P; Dietrich B; Golor G; Schrodter A; Keymeulen B; Lasseter KC; Kipnes MS; Snyder K; Hilliard D; Tanen M; Cilissen C; De Smet M; de Lepeleire I; Van Dyck K; Wang AQ; Zeng W; Davies MJ; Tanaka W; Holst JJ; Deacon CF; Gottesdiener KM; Wagner JA
J Clin Endocrinol Metab; 2006 Nov; 91(11):4612-9. PubMed ID: 16912128
[TBL] [Abstract][Full Text] [Related]
9. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
Neumiller JJ
J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
[TBL] [Abstract][Full Text] [Related]
10. [Analogs of glucagon-like peptide-1 (GLP-1): an old concept as a new treatment of patients with diabetes mellitus type 2].
Diamant M; Bunck MC; Heine RJ
Ned Tijdschr Geneeskd; 2004 Sep; 148(39):1912-7. PubMed ID: 15495988
[TBL] [Abstract][Full Text] [Related]
11. Incretin-based therapy and type 2 diabetes.
Hare KJ; Knop FK
Vitam Horm; 2010; 84():389-413. PubMed ID: 21094909
[TBL] [Abstract][Full Text] [Related]
12. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
Drucker DJ; Nauck MA
Lancet; 2006 Nov; 368(9548):1696-705. PubMed ID: 17098089
[TBL] [Abstract][Full Text] [Related]
13. beta-cell failure in diabetes and preservation by clinical treatment.
Wajchenberg BL
Endocr Rev; 2007 Apr; 28(2):187-218. PubMed ID: 17353295
[TBL] [Abstract][Full Text] [Related]
14. The entero-insular axis: implications for human metabolism.
Ranganath LR
Clin Chem Lab Med; 2008; 46(1):43-56. PubMed ID: 18020966
[TBL] [Abstract][Full Text] [Related]
15. Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors.
Verspohl EJ
Pharmacol Ther; 2009 Oct; 124(1):113-38. PubMed ID: 19545590
[TBL] [Abstract][Full Text] [Related]
16. Incretin hormones: Their role in health and disease.
Nauck MA; Meier JJ
Diabetes Obes Metab; 2018 Feb; 20 Suppl 1():5-21. PubMed ID: 29364588
[TBL] [Abstract][Full Text] [Related]
17. Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes.
Gautier JF; Choukem SP; Girard J
Diabetes Metab; 2008 Feb; 34 Suppl 2():S65-72. PubMed ID: 18640588
[TBL] [Abstract][Full Text] [Related]
18. Incretin-based therapy of type 2 diabetes mellitus.
Knop FK; Vilsbøll T; Holst JJ
Curr Protein Pept Sci; 2009 Feb; 10(1):46-55. PubMed ID: 19275672
[TBL] [Abstract][Full Text] [Related]
19. Incretins and other peptides in the treatment of diabetes.
Todd JF; Bloom SR
Diabet Med; 2007 Mar; 24(3):223-32. PubMed ID: 17263764
[TBL] [Abstract][Full Text] [Related]
20. A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.
Green BD; Gault VA; O'Harte FP; Flatt PR
Diabetes Obes Metab; 2005 Sep; 7(5):595-604. PubMed ID: 16050953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
